– USA, CA – Ambrx Biopharma Inc. (NYSE: AMAM), a clinical-stage biopharmaceutical company today announced the appointments of Edward Hu and Kate Hermans to its Board of Directors.
“I am delighted to welcome both Edward and Kate to Ambrx’s Board. Together, they have decades of experience in business strategy and operations in the pharmaceutical industry on a global scale. I look forward to working closely with Edward and Kate and utilizing their invaluable insight as we continue to progress ARX788 and the rest of our clinical development pipeline,” said Chairman and CEO, Dr. Feng Tian.
About Edward Hu
Edward Hu has more than 25 years of experience in the pharmaceutical industry. Mr. Hu currently serves as Global CIO, an executive director, and as the Vice Chairman of WuXi AppTec Co., Ltd., positions he has held since May 2020. Previously, Mr. Hu served as the Co-CEO of WuXi AppTec Co., Ltd from August 2018 to May 2020, CFO and CIO of WuXi AppTec Co., Ltd from April 2014 to August 2018, COO and CFO of WuXi AppTec Co., Ltd from February 2009 to April 2014, and COO of WuXi AppTec Co., Ltd from August 2007 to February 2009. Mr. Hu serves as a non-executive director of CANbridge Pharmaceuticals, Inc., a position he has held since July 2022, as a non-executive director of WuXi Biologics Inc. from February 2014 to June 2021, and as a director of Viela Bio Inc. from May 2018 to March 2021.
Mr. Hu holds an MBA and an MS in chemistry from Carnegie Mellon University and a bachelor’s degree in physics from Zhejiang University.
About Kate Hermans
Kate Hermans has more than 20 years of experience in the pharmaceutical and healthtech industries. Currently, she is CEO of Hermans International LLC, a commercial and investment advisory firm she founded in 2012 for startup and early-stage enterprises. Previously, Ms. Hermans served as an investor and CBO for 83bar Inc., from December 2018 to July 2021. She served as VP, of Marketing at Radius Health, Inc. from March 2017 to April 2018. Before her time at Radius Health, Inc., Ms. Hermans held commercial and operations executive leadership roles at Bristol Myers Squibb, Pfizer/Wyeth Pharmaceuticals, and the Intel Corporation, working in the U.S., China, Africa, and globally. Ms. Hermans is a Board Director on the Advisory Board of Clue and serves on the Board of Mid-Atlantic Diamond Ventures. Ms. Hermans is also a member of the Healthcare Executive Review Committee for Ben Franklin Tech Partners, a member of the Board of Directors for the Alzheimer’s Association, Delaware Valley Chapter, and the Advisory Board of the Women’s Resource Center.
Ms. Hermans earned a Master of International Management degree from The Thunderbird School of Global Management and a B.A. in International Relations from Wheaton College, MA.
About Ambrx Biopharma Inc.
Ambrx is a clinical-stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include following generation antibody-drug conjugates, biospecific, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety, and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, Ambrx has clinical collaborations with various partners, for drug candidates generated using Ambrx technology.
For more information : https://ambrx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
